Drugs MOA Archives

Itovebi (Inavolisib) Mechanism of Action in Treating Advanced Breast Cancer

a purple and black background with lots of small flowers

Itovebi is a potent kinase inhibitor that has gained attention in the treatment landscape for advanced breast cancer, particularly when used in combination with other therapeutic agents like palbociclib and fulvestrant. Its primary indication lies in targeting specific breast cancer subtypes, notably endocrine-resistant, PI3KCA-mutated, HR-positive, and HER2-negative breast cancer in adult patients. This specificity is … Read more

Mechanism of Action of Donanemab-azbt for Alzhenimer’s

by Ahmed

Mechanism of Action of Donanemab kisunla old ladies taking a selfie

Donanemab got FDA approval on 2nd July 2024. The mechanism of action of Donanemab-azbt (Kisunla) is detailed here to understand how this new molecule can be a life-changer for people with Alzheimer’s disease. Kisunla (Donanemab) is a special type of medicine known as a monoclonal antibody. Monoclonal antibodies are lab-made molecules designed to fight diseases … Read more

Daratumumab Mechanism of Action: Darzalex MOA

by Ahmed

Daratumumab Mechanism of Action: Daratumumab is a human monoclonal antibody. It is indicated for the treatment of Multiple Myeloma in the following situations: In Combination With … Daratumumab Indications Lenalidomide + dexamethasone Newly diagnosed Multiple Myeloma patients ineligible for autologous stem cell transplant OR Patients with relapsed or refractory multiple myeloma who have received at … Read more

Linzess MOA: Mechanism of Action of Linaclotide

by Ahmed

linzess moa abdominal pain why is linzess dangerous

Linzess MOA (Mechanism of action) is different from most other medications used to treat constipation and IBS (Irritable Bowel Syndrome) such as Miralax. Linzess (Linaclotide) is the first-in-class medicine that acts on the intestinal epithelial cells and stimulates the transmembrane Guanylate Cyclase 2C receptors (GC-2C). Activation of guanylate cyclase 2 C receptors results in the … Read more

Nubeqa Mechanism of Action (Darolutamide MOA)

by Ahmed

darolutamide moa mechanism of action of nubeqa

Darolutamide MOA is discussed in this article. It is a recently approved chemotherapeutic drug for the treatment of prostate cancer. Drug Name: Darolutamide MOA Brand Name: Nubeqa The prostate is a prevalent malignancy that commonly affects elderly males. Most prostate cancers are responsive to hormones. A therapeutic objective is to impede their proliferation by inhibiting … Read more

Trofinetide MOA (Mechanism of Action of Daybue)

by Ahmed

Trofinetide daybue moa for rett syndrome

Trofinetide MOA (Mechanism of action): Trofinetide is a synthetic peptide that has been developed as a potential treatment for Rett syndrome, a rare neurodevelopmental disorder that affects mainly girls. The mechanism of action of Trofinetide (Trofinetide MOA) is not fully understood, but it is believed to involve several different pathways in the brain. One of … Read more

mTOR Inhibitor Everolimus (Afinitor): MOA, Side effects, Dose

by Ahmed

mTOR inhibitor Everolimus Afinitor trucap hyperglycemia

Novartis’ Afinitor (everolimus) was approved by the FDA on February 26, 2016, for the treatment of adult patients with unresectable, locally advanced or metastatic progressive, well-differentiated non-functional neuroendocrine tumors (NETs) originating from the gastrointestinal or lung areas. Afinitor, also known as everolimus, is a type of medication categorized as an mTOR inhibitor. It is available … Read more

Tremelimumab MOA (Mechanism of Action of Imjudo)

by Ahmed

Tremelimumab is marketed by name, Imjudo. It is a CTLA-4 inhibitor that has been approved for the treatment of unresectable HCC and non-small-cell carcinoma. What is CTLA-4? CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a protein receptor that is expressed on the surface of T-cells (a type of immune cell). It functions as a negative regulator … Read more

Tysabri (Natalizumab) MOA and Indications

by Ahmed

Tysabri contains “Natalizumab” considered an evolution in the management of many autoimmune diseases. It is manufactured by Biogen Company and got FDA approval in 2004. In 2005 the drug was voluntarily withdrawn from the U.S. market when cases of progressive multifocal leukoencephalopathy were reported. However, it was again approved by FDA in 2006 due to … Read more

Tofacitinib Mechanism of Action: Xeljanz MOA

by Ahmed

Tofacitinib is an oral Janus Kinase Inhibitor. Because of its unique and novel mechanism of action, it is one of the potent JAK Inhibitors. It was approved by the FDA in 2012. It is available in two formulations: Immediate Release as Xeljanz, and The Extended Release Oral Tablets as Xeljanz XR Tofacitinib is a Janus … Read more